Tonix Pharmaceuticals is currently enrolling participants in a Phase 3 trial for posttraumatic stress disorder (PTSD). For more information, please visit www.recoverystudy.com or www.clinicaltrials.gov (NCT03841773).

News / Press Releases

: Press Releases

Press Releases

Tonix Pharmaceuticals to Present at BIO-Europe International Partnering Conference

November 1, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Innovative Design in Next Phase 3 Study of Tonmya® for PTSD, Following FDA Meeting

October 31, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals will Present Phase 3 HONOR and Phase 2 AtEase Study Results in Poster Presentations at CNS Summit 2018

October 29, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the Dawson James Securities Small Cap Growth Conference

October 23, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at the MicroCap Conference

September 26, 2018 • 1:30 PM EDT

Tonix Pharmaceuticals to Present at Sidoti & Company Fall 2018 Investor Conference

September 20, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces New Board Member, Oye Olukotun, M.D.

September 7, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals to Present at Upcoming September Investor Conferences

August 30, 2018 • 7:00 AM EDT

Tonix Pharmaceuticals Announces Director Stepping Down

August 22, 2018 • 4:01 PM EDT

Tonix Pharmaceuticals Presents Results and Retrospective Analyses of Two Double-Blind, Randomized Placebo-Controlled 12-Week Studies of Tonmya® in Military-Related PTSD at the 2018 Military Health System Research Symposium

August 21, 2018 • 7:00 AM EDT

« Previous
1
2
3
4
5
6
7
8
9
10
...30
Next »

Show All

News / Press Releases : Press Releases